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measurement experts to generate items, responses, and instructions for the new scale. 
Cognitive interviews were conducted with an additional 15 idiopathic RLS patients 
(aged 25–68) to ensure understanding of the new measure, concept comprehensive-
ness, and to identify any necessary revisions to the items and conceptual framework. 
RESULTS: Twenty-three items were generated from patient quotes obtained during 
the concept elicitation interviews. Impacts on next day functioning spontaneously 
attributed to disturbed sleep due to RLS symptoms included: activities of daily living 
(i.e., work, household chores), cognitive functioning (i.e., concentration, forgetfulness, 
mental tiredness, alertness), emotional functioning (i.e., irritability, depressed mood), 
physical functioning (i.e., physical tiredness, active leisure activities), energy, daytime 
sleepiness, and social functioning (i.e., relationships, social activities/situations). 
Concept saturation was achieved. Modiﬁcations to questions and responses were 
based on feedback provided during cognitive interviews. The ﬁnal measure consists 
of 14 items assessed “today” and rated on a severity numeric rating scale. CONCLU-
SIONS: The RLS-NDI is an evaluative tool with demonstrated content validity to 
assess the impact of disturbed sleep due to RLS symptoms on RLS patients’ next day 
functioning.
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OBJECTIVES: Parkinson’s disease (PD) is the second most prevalent neurodegenera-
tive disorder in the US. The Scales for Outcomes in Patients with Parkinson’s disease 
Diary Card (SCOPA-DC) is a daily diary designed to measure motor impairment in 
PD patients with ﬂuctuating symptoms. Consistent with the FDA’s ﬁnal guidance on 
patient-reported outcome measures, this study aimed to evaluate the content validity 
of the SCOPA-DC in the US and determine the feasibility of adding items that measure 
non-motor symptoms using qualitative techniques. METHODS: A literature review 
identiﬁed the most dominant non-motor symptoms experienced by PD patients with 
ﬂuctuating symptoms. Three focus groups were conducted with PD patients (n = 24) 
to identify themes that speciﬁcally addressed the study objectives. The original 
SCOPA-DC was modiﬁed based on ﬁndings from the literature review and patient 
input. A fourth focus group (n = 9) consisted of a cognitive debrieﬁng of the revised 
SCOPA-DC that included additional items and modiﬁed structure based upon the 
previous results. RESULTS: Findings from the focus groups demonstrated support for 
the content of the original SCOPA-DC, generally ﬁnding it to be clear and intuitive, 
despite difﬁculties with some item deﬁnitions, time frames, and response labels. With 
respect to non-motor symptoms, seven domains were consistently mentioned: fatigue, 
concentration/memory, anxiety, pain, difﬁculty swallowing, frequent urination, and 
sweating. The cognitive debrieﬁng focus group reported that the revised SCOPA-DC 
format was easier to use, provided better focus on the items and time frames, and 
more adequately captured experiences throughout the day as compared to the original. 
CONCLUSIONS: Non-motor symptoms occur frequently in PD patients with ﬂuctu-
ating symptoms and have a signiﬁcant impact on health-related quality of life. A 
reliable and validated patient-reported daily diary may improve the ability to describe 
PD progression by accurately measuring both motor and non-motor symptoms. Addi-
tional quantitative research is needed to evaluate the psychometric properties of the 
revised SCOPA-DC.
PND26
VALIDATING USE OF THE MIGRAINE-SPECIFIC QUALITY OF LIFE 
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OBJECTIVES: To provide evidence for the reliability and validity of the Migraine-
Speciﬁc Quality of Life Questionnaire Version 2.1 (MSQ) for use across migraine 
disorders. METHODS: Cross-sectional data were collected via web-based survey in 
nine countries/regions. Participants were classiﬁed per ICHD-2 criteria as having 
chronic migraine (CM, ≥15 headache days/month), high-frequency episodic migraine 
(HEM, 10–14 headache days/month), or low-frequency episodic migraine (LEM, ≤9 
headache days/month). Three MSQ domains Role Function-Preventive (RP), Role 
Function-Restrictive (RR), and Emotional Function (EF) were rescaled to 0–100, 
where higher scores indicate better health-related quality of life (HRQOL), and ana-
lyzed for internal consistency reliability (Cronbach’s alpha), construct validity (cor-
relations assessed between MSQ scales and measures of depression/anxiety [Patient 
Health Questionnaire; PHQ-4], disability [Migraine Disability Assessment Question-
naire; MIDAS], and functional impact [Headache Impact Test; HIT-6], where lower 
scores indicate better HRQOL for each), as well as discriminant validity across 
migraine groups. RESULTS: A total of 8726 eligible respondents were classiﬁed as 
follows: 5.7% CM (n = 499), 5.9% HEM (n = 515), and 88.4% LEM (n = 7,712). 
Migraineurs were mostly female (83.5%) with a mean (±SD) age of 40.3 ± 11.4, 
similar across the groups. MSQ domain scores for CM, HEM, and LEM groups 
respectively were: RP = 61.4 ± 26.1, 65.9 ± 23.8, and 72.1 ± 23.9; RR = 44.4 ± 22.1, 
48.3 ± 22.8, and 57.0 ± 24.1; EF = 48.3 ± 28.1, 57.8 ± 27.7, and 67.8 ± 26.5. Internal 
consistency of the total sample for RP, RR, and EF was 0.90, 0.96, and 0.87, respec-
tively. Similar values were observed across migraine groups. Varied by domains and 
migraine groups, MSQ scores correlated moderately to highly with scores from the 
PHQ-4 (r = −0.28 to −0.47), MIDAS (r = −0.42 to −0.58), and HIT-6 (r = −0.55 to 
−0.71). Known groups validity indicated signiﬁcant differences (p < 0.0001) in the 
hypothesized direction between CM, HEM, and LEM for RP (F = 58.74), RR (F = 
91.78), and EF (F = 153.38). CONCLUSIONS: The MSQ is a reliable and valid 
questionnaire that can differentiate the functional impact between CM, HEM, and 
LEM.
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OBJECTIVES: The Migraine-Speciﬁc Quality of Life Questionnaire Version 2.1 
(MSQ) is a 14-item health-related quality of life instrument that measures the func-
tional impact of migraine across three domains: Role Function-Preventive (RP), Role 
Function-Restrictive (RR), and Emotional Function (EF). This study evaluated the 
factor structure and cross-cultural comparability of the MSQ in Chronic Migraine 
(CM) sufferers. METHODS: Cross-sectional data were collected via web-based 
survey, across eight countries. Respondents were classiﬁed as having CM per ICHD-2 
criteria with ≥15 headache days/month (n = 499). Conﬁrmatory factor analysis (CFA) 
of the 3-factor model was conducted using the robust maximum likelihood estimator 
(MLR) assuming multivariate normality. Goodness-of-ﬁt was assessed by the com-
parative ﬁt index (CFI), Tucker-Lewis Index (TFI), and root mean square error of 
approximation (RSMEA). Differential item functioning (DIF) was tested using ordinal 
logistic regression of MSQ item scores on group membership and trait level explana-
tory variables. Groups were based on country (Australia, Canada, Germany, Spain, 
France, Great Britain, Italy, United States) and language (English/non-English). Non-
uniform DIF (signiﬁcant interaction term between group membership and trait level, 
p < 0.05) and uniform DIF (>10% change in the trait level coefﬁcient resulting from 
removal of the group membership term from the model) were identiﬁed. RESULTS: 
The 3-factor model demonstrated good ﬁt (CFI = 0.97; TFI = 0.96; RMSEA = 0.07) 
among CM sufferers. Factor loadings ranged between 0.72 and 0.89, and had similar 
values across the three factors. Most MSQ items showed absence of DIF. Non-uniform 
country DIF was identiﬁed in items 5 (inability to concentrate; p = 0.028) and 12 (fed 
up or frustrated; p = 0.037). Item 12 also presented non-uniform DIF related to 
language (p = 0.010). CONCLUSIONS: Among Chronic Migraineurs, the MSQ 
provides a valid measure of RP, RR, and EF, yielding domain scores that can be reli-
ably compared across languages and countries.
PND28
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OBJECTIVES: Increasingly health status measures, used to measure the subjective 
functioning and well being of respondents, are being used in trials of treatments which 
are undertaken in a variety of countries. The purpose of this study was to evaluate 
the psychometric properties of a short form health survey, the Parkinson’s Disease 
Questionnaire (PDQ-8), cross-culturally, by comparing results gained from this instru-
ment to the original longer form instrument—the PDQ-39. METHODS: Data are 
from the Global Parkinson’s Disease Survey (GPDS) a cross national survey which 
utilised the thirty nine item Parkinson’s Disease Questionnaire (PDQ-39) as a major 
outcome measure. In this study, we evaluate results from the PDQ-8 (Single Index 
Score PDQ-8-SI) with results from the parent form (from which the PDQ-8 was 
derived), of the instrument in the USA, Canada, Spain, Italy and Japan. RESULTS: 
We evaluate response rate (97% of the 819 respondents completed all items on 
PDQ-8), data quality, score reliability (internal reliability of the eight items of the 
PDQ-8 was calculated for all countries using Cronbach’s alpha, USA = 0.88; Canada 
= 0.83; Italy = 0.87; Spain = 0.79 and Japan = 0.73) and scaling assumptions of the 
instrument in the USA, Canada, Spain, Italy and Japan. CONCLUSIONS: The evi-
dence suggests that PDQ-8-SI seems a useful measure in studies where a short measure, 
providing an overall index of self perceived health in PD, is required. The PDQ-8 is 
a practical and informative instrument for the evaluation of overall quality of life of 
PD patients in cross-cultural studies.
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OBJECTIVES: Bladder dysfunction is a common symptom in patients with multiple 
sclerosis (MS). This study assessed the current literature regarding instruments that 
have been used to measure the health-related quality of life (HRQOL) impact of this 
chronic illness, and to what extent bladder dysfunction affects HRQOL in this popula-
tion. METHODS: Two searches using MEDLINE/PubMed’s MeSH database were 
made. Quality of life was isolated by checking the psychology subheading within the 
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multiple sclerosis heading term or by using quality of life and multiple sclerosis as 
separate MeSH terms. Urinary bladder was entered as a heading term, and all associ-
ated subheadings were included in the search box. Studies were included if a HRQOL 
instrument measuring bladder function or urinary incontinence was administered to 
a sample of MS patients. References in these articles were searched for additional 
studies that met inclusion criteria. RESULTS: Six articles initially met inclusion crite-
ria. An additional 2 articles were found from their references. A total of 8 different 
instruments were used ranging from 6 to 30 items and tested across 3 to 10 different 
domains. Articles varied in terms of sample size (30 to 9,688 participants), study 
design (cross-sectional vs. prospective cohort), and objectives (HRQOL impact vs. 
instrument validation). Six disease-speciﬁc HRQOL instruments were originally 
designed for use in other populations, and 3 were gender speciﬁc. Moderate to severe 
bladder dysfunction in patients with MS was prevalent in 49% to 79% of the study 
samples and the urinary symptoms negatively impacted HRQOL in all the studies. 
CONCLUSIONS: The use of HRQOL instruments speciﬁc to bladder dysfunction in 
patients with MS is limited. Study design variability made it difﬁcult to assess overall 
impact of bladder symptoms on HRQOL. Further validation of existing instruments 
that include both sexes and whose bladder dysfunction is of neurogenic origin is 
needed.
PND30
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OBJECTIVES: To evaluate changes in patient-reported fatigue and cognitive function 
after one year of natalizumab treatment in MS patients. METHODS: The study popu-
lation consists of MS patients initiating natalizumab treatment who agreed to partici-
pate in a 12-month longitudinal study. The study assessed patient experiences with 
natalizumab using validated patient-reported outcome (PRO) measures prior to treat-
ment initiation and after 3rd, 6th and 12th infusions. The current analysis reports change 
in fatigue and cognitive functioning from baseline through the 12th natalizumab infu-
sion. Fatigue is measured by the 5-question Modiﬁed Fatigue Impact Scale-5 (MFIS-5, 
score range 0–20) with lower scores indicating lower impact of fatigue on physical, 
cognitive, and psychosocial functioning; cognitive function is measured by the 6-ques-
tion Medical Outcomes Study Cognitive Functioning Scale (MOS-Cog Scale, score 
range 6–36) with higher scores indicating better reasoning skills, memory, concentra-
tion, ability to start several actions at one time and ability to react to what is said or 
done. Regression analysis was used to control for baseline (BL) covariates such as age, 
years since MS diagnosis, number of natalizumab infusions received, MS level of dis-
ability and functional status, number of MS drugs used prior to natalizumab and 
comorbidity burden. RESULTS: Results from this on-going study are presented for 
192 patients completing the BL through 12th infusion follow-up surveys. The mean 
number of years since MS diagnosis was 10.16 (SD = 8.23). Most patients were female 
(78%) and the mean age was 46.09 (SD = 10.78). On average, MFIS scores decreased 
signiﬁcantly (BL 12.23 ± 2.2; 12th infusion score 10.97 ± 2.2, p < 0.001) and MOS-Cog 
scores increased signiﬁcantly over time (BL 25.8 ± 1.4; 12th infusion score 26.91 ± 
1.4, p < 0.001) after controlling for covariates. CONCLUSIONS: MS patients 
reported improvements in the impact of fatigue and overall cognitive function after 
one year of natalizumab treatment.
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OBJECTIVES: To assess the change in general health-related quality of life (HRQoL) 
of multiple sclerosis (MS) patients after one year of natalizumab treatment. 
METHODS: MS patients, newly starting natalizumab, were recruited to participate 
in a longitudinal observational study to assess general health-related quality of life 
using the SF-12v2 prior to natalizumab initiation and after the 3rd, 6th and 12th infu-
sions. Higher physical component summary scores (PCS) and mental component 
summary scores (MCS) on the SF-12v2 indicate better HRQoL. Statistical regression 
models were used to evaluate changes in PCS and MCS scores from baseline through 
the 12th infusion after controlling for baseline patient-level and treatment characteris-
tics. RESULTS: Data for 192 patients who had completed the baseline through 12th 
infusion assessments of this ongoing study are reported. The mean age was 46.09 (SD 
= 10.78) and the majority of patients were female (78%). The mean number of years 
since MS diagnosis was 10.16 (SD = 8.23). The PCS score improved signiﬁcantly from 
baseline (BL 33.30 ± 7.12, 12th infusion 35.91 ± 7.12; p < 0.001); similar improve-
ments were observed in the MCS scores which also improved signiﬁcantly from 
baseline (BL 43.12 ± 1.53, 12th infusion 47.95 ± 1.53; p < 0.001). CONCLUSIONS: 
Patients reported improvements in general HRQoL measures after one year of natali-
zumab treatment in the usual care setting. These results are consistent with results 
from pivotal clinical trials and document the beneﬁcial impact of natalizumab on 
HRQoL of MS patients.
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OBJECTIVES: To assess duloxetine utilization among commercially-insured ﬁbromy-
algia patients. METHODS: This study analyzed administrative claims for ﬁbromyalgia 
patients aged 18–64 who initiated duloxetine in 2006. Initiation was deﬁned as no 
duloxetine coverage in the prior 90 days, with the ﬁrst duloxetine prescription dispense 
date as the “index date.” Patients were excluded if they had less than 30 duloxetine 
supply days in the 12-month post-index period, or diagnosis of diabetic peripheral 
neuropathic pain or depression in the 12 months pre-index period. All duloxetine 
patients were classiﬁed in ﬁve cohorts based on index dosage: <30 mg, 30 mg, 
31–59 mg, 60 mg, and >60 mg. Changes in dosage, average daily dosage (ADD), and 
adherence to duloxetine (medication possession ratio ≥0.8 as high adherence) were 
compared across cohorts. Multivariate regression models were performed to examine 
the association between index dosage and health care costs, controlling for demo-
graphics and clinical characteristics. RESULTS: Of 4,869 ﬁbromyalgia patients identi-
ﬁed, 4.4% had an index dosage of <30 mg, 22.4% of 30 mg, 5.9% of 31–59 mg, 
60.4% of 60 mg, and 7.0% of >60 mg. 28% of total patients experienced any increase 
in dosage, while 15.9% experienced any decrease. Among those with any dosage 
change (n = 1,651), patients with an index dosage of 31–59 mg had the shortest 
duration before any dosage change (89 days), followed by those in the <30 mg, 
>60 mg, 30 mg, and 60 mg (95, 100, 104, and 139 days, respectively) cohorts. ADD 
increased with index dosage. Patients with <60 mg index dosage were less likely to 
be adherent than those in the 60 mg cohort (odds ratios ranged 0.61 to 0.78, all p < 
0.05). Patients in the >60 mg cohort had higher total health care costs compared with 
those in the 60 mg cohort (adjusted difference: $3,747, p < 0.05). CONCLUSIONS: 
About one-third of duloxetine treated ﬁbromyalgia patients experienced any dosage 
change. Duloxetine adherence and ADD, and health care costs differ by duloxetine 
index dosage.
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OBJECTIVES: Multiple pharmacologic therapies have been recommended for manag-
ing ﬁbromyalgia. However, the factors associated with each treatment initiation have 
not been well established. This study assessed demographic and clinical predictors of 
duloxetine versus other pain medications dispensed among patients with ﬁbromyalgia. 
METHODS: Employing a retrospective cohort design and data from commercial 
insurance, this study examined predictors of treatment among ﬁbromyalgia patients 
who were 18 to 64 years old and initiated duloxetine versus selective serotonin reup-
take inhibitors (SSRIs), tricyclic antidepressants (TCAs), venlafaxine, gabapentin, 
pregabalin, tramadol or non-tramadol narcotics between January 1, 2007 and Decem-
ber 31, 2008. Treatment initiation was deﬁned as no access to the same medication 
over the previous 90 days, and the most recent initiation date was set as the index 
date. All patients selected had at least 1 ﬁbromyalgia diagnosis (ICD-9-CM: 729.1) in 
the 12 months prior to initiation of each study therapy. Multiple logistic regression 
models were estimated to assess predictors of initiating duloxetine versus each of the 
other ﬁbromyalgia therapies. RESULTS: Commercially insured ﬁbromyalgia patients 
(n = 117,305) were on average 48 years of age, and 76% were females. Common 
ﬁbromyalgia-related comorbidities were low back pain (35%), osteoarthritis (17%), 
and diabetes (12%). After controlling for demographic and clinical characteristics, 
those 35+ years of age, females, and patients who received SSRIs, TCAs, venlafaxine, 
gabapentin, or pregabalin over the 1-year pre-index period were generally more likely 
to initiate duloxetine than the other study medications. Other predictors of duloxetine 
initiation included higher prescription copayment and history of rheumatoid arthritis, 
osteoporosis, and sleep disturbance. CONCLUSIONS: These ﬁndings indicate that 
age, cost sharing, presence of selected comorbidities, and prior use of certain medica-
tions to treat pain were signiﬁcant predictors of duloxetine initiation among working 
age, commercially insured ﬁbromyalgia patients.
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OBJECTIVES: Medications are critical for preventing and controlling migraine head-
aches. The objectives of this project are to describe anti-migraine drug (AMD) utiliza-
tion, price and reimbursement trends, and to compare market share competitions 
between Ergots and serotonin 5-HT1 receptor agonists (triptans). METHODS: Study 
drugs included ergot derivatives and triptans. A retrospective, descriptive time-series 
analysis was conducted for this study. The data source is the national Medicaid 
pharmacy claim database from CMS. The quarterly prescription numbers and reim-
bursement amounts were calculated from 1st quarter 1991 to 4th quarter 2008. The 
